MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Dividend History

Company News

• Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

  The FDA has approved Merck's Keytruda for use as a neoadjuvant and adjuvant treatment for certain patients with head and neck cancer, making it the first immunotherapy approved for use around surgery for this indication.

  Benzinga

  Featured Companies: MRK
• Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

  The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.

  GlobeNewswire Inc.

  Featured Companies: ANAB
• Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

  MoonLake Immunotherapeutics (MLTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  Zacks Investment Research
• The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

  Forget about the Magnificent Seven and AI. The stocks that did the absolute best during the year were tied to biotech and crypto — along with one car-related company.

  MarketWatch

  Featured Companies: AAPL AFRM AMZN BBIO CIFR CLSK CVNA DJIA GOOG GOOGL KMX MARA META MSFT NVDA RIOT SLNO TSLA
• Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

  A competitor's clinical trial stumble may be benefiting MoonLake.

  The Motley Fool